Abstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose. An extensive clinical program involving approximately 22,000 patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well tolerated and effi cacious in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Monotherapy trials have shown that signifi cant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy. Studies of vildagliptin as an add-on to metformin have shown signifi cant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course. Keywords: diabetes, vildagliptin, incretin, metformin, add-on treatment, hypoglycemia Type 2 diabetes mellitus (T2DM) is a dual disease, characterized by islet (beta-and alpha-) cell dysfunction in the setting of insulin resistance. Moreover, ample clinical evidence, such as data from the landmark UK Prospective Diabetes Study (UKPDS), indicates that loss of beta-cell function is progressive. This progressive decline leads to the clinical impression of failure of therapy in T2DM patients and is the main reason why so many patients with T2DM are not within target ranges of glycemic control. Moreover, the clear alpha-cell dysfunction that is also present in T2DM has been disregarded in previous years, mainly because therapeutic interventions were lacking. The need to address this underlying islet cell defi cit led to a search for therapeutic alternatives and has led to the rediscovery of the incretin hormones and their role in glucose homeostasis. Improved understanding of their potential has led in turn to the development of incretin analogs and incretin enhancers for treatment of T2DM (Deacon 2004; Vilsbøll and Holst 2004; Drucker 2006; Deacon et al 2008) .
Type 2 diabetes mellitus (T2DM) is a dual disease, characterized by islet (beta-and alpha-) cell dysfunction in the setting of insulin resistance. Moreover, ample clinical evidence, such as data from the landmark UK Prospective Diabetes Study (UKPDS), indicates that loss of beta-cell function is progressive. This progressive decline leads to the clinical impression of failure of therapy in T2DM patients and is the main reason why so many patients with T2DM are not within target ranges of glycemic control. Moreover, the clear alpha-cell dysfunction that is also present in T2DM has been disregarded in previous years, mainly because therapeutic interventions were lacking. The need to address this underlying islet cell defi cit led to a search for therapeutic alternatives and has led to the rediscovery of the incretin hormones and their role in glucose homeostasis. Improved understanding of their potential has led in turn to the development of incretin analogs and incretin enhancers for treatment of T2DM (Deacon 2004; Vilsbøll and Holst 2004; Drucker 2006; Deacon et al 2008) .
The present review will discuss the data available on the incretin enhancer vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of the incretin hormones glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). This activity increases levels of active incretins and enhances pancreatic islet α-and β-cell responsiveness to glucose, thus improving insulin secretion and reducing inappropriate glucagon production, improving insulin sensitivity, improving postprandial lipid and lipoprotein metabolism, and reducing fasting and prandial glucose and HbA1c (Ahrén et Azuma et al 2008; Deacon et al 2008) . Finally, we will discuss the best position for this drug in our therapeutic arsenal to address glycemic control in T2DM patients.
Vildagliptin: clinical program
Most data available on vildagliptin until now have come from company-sponsored studies designed for registration purposes. The drug has been evaluated in an extensive, ongoing clinical program, involving approximately 22,000 treated patients overall and 14,200 vildagliptin-treated patients representing approximately 7000 subject-years of vildagliptin exposure as of April 2008 (data on fi le, Novartis). It is currently approved for use in treatment of T2DM in the European Union, Latin America (Brazil, Mexico), and Asia (Korea, Singapore, Philippines). As reviewed herein, clinical trials have shown that vildagliptin improves glycemic control in patients with T2DM as monotherapy (Pi-Sunyer et al 2007; Dejager et al 2007; Rosenstock et al 2007a; Schweizer et al 2007; Pan et al 2008) and as add-on or initial combination therapy with other oral antidiabetic agents and insulin (Bosi et al 2007a; Fonseca et al 2007; Garber et al 2007; Rosenstock et al 2007b; Bolli et al 2008; Garber et al 2008) , as well as in patients with impaired glucose tolerance (IGT) (Rosenstock et al 2008; Utzschneider et al 2008) . Recent evidence from T2DM patients with mild hyperglycemia indicates that vildagliptin attenuates deterioration of β-cell function over long-term treatment (Mari 2008; Scherbaum 2008a; Scherbaum 2008b ). Vildagliptin treatment is characterized by weight-neutral and lipid-neutral effects, very low risk of edema, and very low risk of hypoglycemia.
T2DM is characterized by continual loss of glycemic control despite treatment, with few patients achieving and maintaining treatment goals and combination treatment typically becoming unavoidable (UKPDS 1998; Saydah 2004; Kahn 2006) . Current guidelines encourage a prompt move to combination treatment when initial metformin treatment fails to achieve glycemic goals (Nathan et al 2006) . The primary utility of vildagliptin is likely to be as add-on treatment or in initial combination with metformin. These agents have complementary effects in improving glycemic control, potential mechanistic synergy, and a favorable interaction of tolerability profi les, including absence of risk for weight gain, edema, and hypoglycemia. In the European Union, vildagliptin (Galvus ® ) is approved for use at 50 mg bid in combination with metformin or a thiazolidinedione and at 50 mg qd in combination with a sulfonylurea (SU). A fi xed-dose vildagliptin/metformin combination is approved for use in 50 mg/850 mg and 50 mg/1000 mg formulations.
Pharmacologic overview
Vildagliptin is rapidly absorbed after oral administration, with approximately dose-proportional pharmacokinetics (He 2007b; He 2007c) . No dosage adjustment is necessary based on age, gender, body mass index (BMI), food intake, presence of hepatic impairment, or concomitant use of commonly used drugs (He et al 2008a; He et al 2007d; He et al 2007e; He et al 2007f; Sunkara 2007; He et al 2008b) . Bioequivalence of the fi xed-dose combination of vildagliptin and metformin with the individual components has been shown; the effect of food in decreasing metformin exposure was smaller with the metformin component in the fi xed-dose combination than has been reported with metformin alone, and the fi xed-dose combination can thus be administered in the same manner as metformin alone (He et al 2008c; He et al 2008d) .
Vildagliptin monotherapy trials
Vildagliptin has been evaluated as monotherapy in treatmentnaïve T2DM patients in randomized, double-blind doseranging and comparative trials, including comparisons with metformin, rosiglitazone, and acarbose; in subjects with impaired glucose tolerance; and in T2DM patients with mild hyperglycemia.
Dose-ranging studies
In one dose-ranging study, 354 patients (HbA1c 7.5%-10.0%, baseline average 8.4%) were randomized to vildagliptin 50 mg qd (n = 88), 50 mg bid (n = 83), or 100 mg qd (n = 91) or to placebo (n = 92) for 24 weeks (Pi-Sunyer 2007) . Placebo-subtracted mean changes from baseline in HbA1c were 0.5%, 0.7%, and 0.9%, respectively, in the three vildagliptin dose groups (all p Յ 0.01 vs placebo). Placebo-subtracted reductions from baseline fasting plasma glucose (FPG; baseline average 10.5 mmol/L) were 0.6, 1.3, and 1.3 mmol/L, respectively (p Ͻ 0.001 for latter two dose groups). Adverse events occurred with similar frequency with vildagliptin (55.8%-59.3%) and placebo (57.6%). There was no signifi cant change in weight, and no episodes of hypoglycemia occurred with vildagliptin treatment. In a second dose-ranging study, 632 patients (HbA1c 7.5%-11.0%, baseline 8.4%) were randomized to vildagliptin 50 mg qd (n = 163), 50 mg bid (n = 152), or 100 mg qd (n = 157) or to placebo (n = 160) for 24 weeks . Changes in HbA1c from baseline were −0.3% with placebo vs −0.8%, −0.8%, and −0.9% with vildagliptin 50 mg qd, 50 mg bid, and 100 mg qd, respectively (p Ͻ 0.01 for all). Body weight decreased by 0.3-1.8 kg across all groups. Mild hypoglycemia occurred in 2 patients (1.2%) receiving vildagliptin 50 mg qd, in 1 patient (0.6%) receiving 100 mg qd, and in none of the patients receiving 50 mg bid or placebo.
Comparison with metformin
In a noninferiority trial, 780 patients (HbA1c 7.5%-11.0%, average 8.7%) were randomized to vildagliptin 50 mg bid (n = 526) or metformin 1000 mg bid (n = 254) for 52 weeks . Mean changes in HbA1c were −1.0% with vildagliptin (p Ͻ 0.001) and −1.4% with metformin (p Ͻ 0.001), with the criterion for noninferiority not being met by vildagliptin. In patients with baseline HbA1c Յ8% (mean ∼7.6%), mean changes at 24 weeks were similar with vildagliptin (−0.6%, n = 180) and metformin (−0.7%, n = 79). In an extension study, where patients were on treatment for 2 years, HbA1c reductions were sustained at −1.0% with vildagliptin (n = 243) and −1.5% with metformin (n = 136) (data on fi le, Novartis).
Over 52 weeks, there was no significant change in body weight with vildagliptin and a 1.9-kg weight loss with metformin (p Ͻ 0.001), and hypoglycemia occurred in 0.6% of vildagliptin patients and 0.4% of metformin patients. Adverse events were similar in frequency with vildagliptin (70.1%) and metformin (75.4%), but vildagliptin was associated with signifi cantly fewer gastrointestinal (GI) adverse events (22% vs 44%, p Ͻ 0.001). Among patients with diastolic blood pressure (DBP) Ն90 mmHg (vildagliptin, n = 89; metformin, n = 53; baseline 94 mmHg) or systolic blood pressure (SBP) Ն140 mmHg (vildagliptin, n = 150; metformin, n = 84; baseline 149-150 mmHg), vildagliptin was associated with a signifi cantly greater decrease in DBP (7.5 vs 4.2 mmHg, p Ͻ 0.05) and SBP (9.1 vs 5.3, p Ͻ 0.05) (Bosi 2 et al 007b).
Comparison with rosiglitazone
In a noninferiority trial, 786 patients (HbA1c 7.5%-11.0%, mean ∼8.7%) were randomized to vildagliptin 50 mg bid (n = 519) or rosiglitazone 8 mg qd (n = 267) for 24 weeks (Rosenstock et al 2007a) . Mean changes in HbA1c from baseline were −1.1% with vildagliptin vs -1.3% with rosiglitazone, with vildagliptin meeting the noninferiority criterion. Among patients with baseline HbA1c Ͼ 9.0% (vildagliptin, n = 166; rosiglitazone, n = 88; mean ∼10.0%), mean reductions were 1.8% vs 1.9%. Overall, vildagliptin was associated with a 0.3-kg reduction in body weight, vs a 1.6-kg increase with rosiglitazone (p Ͻ 0.001); among patients with baseline BMI Ն 35 kg/m 2 (vildagliptin, n = 132; rosiglitazone, n = 76; body weight 111-112 kg), vildagliptin patients lost 1.1 kg, compared with a gain of 1.7 kg with rosiglitazone (p Ͻ 0.001). The frequency of adverse events was similar in the two groups (61.4% and 64.0%), and one case of mild hypoglycemia occurred in each group. Peripheral edema was reported in 2.1% of vildagliptin patients and 4.1% of rosiglitazone patients. Changes in atherogenic lipids consisted of small decreases with vildagliptin and moderate increases with rosiglitazone in triglycerides (p = 0.01), total cholesterol (p Յ 0.003), and LDL cholesterol (p Յ 0.003), with a greater increase in HDL cholesterol occurring with rosiglitazone (p Յ 0.003).
Comparison with acarbose
In a noninferiority trial, 661 patients (HbA1c 7.5%-11.0%, mean ∼8.6%) were randomized to vildagliptin 50 mg bid (n = 441) or acarbose up to 100 mg tid (n = 220) for 24 weeks (Pan et al 2008) . Mean changes in HbA1c were 1.4% with vildagliptin and 1.3% with acarbose, with vildagliptin meeting the noninferiority criterion. Among patients with baseline HbA1c Ͼ9.0% (vildagliptin, n = 146; acarbose, n = 63; mean ∼9.8%), reductions were 2.0% and 2.1%, respectively. Body weight decreased by 0.4 kg with vildagliptin and by 1.7 kg with acarbose (p Ͻ 0.001). Adverse events occurred in 35% of vildagliptin patients and in 51% of acarbose patients, with a signifi cant reduction in GI adverse events with vildagliptin (12.3% vs 25.5%, p Ͻ 0.001). No hypoglycemia occurred in either group.
Impaired glucose tolerance
In a randomized, double-blind trial, 179 subjects with IGT (2-h glucose 9.1 mmol/L, HbA1c 5.9%) were randomized to vildagliptin 50 mg qd (n = 90) or placebo (n = 89) for 12 weeks (Rosenstock et al 2008) . Compared with placebo, vildagliptin signifi cantly increased levels of GLP-1 and GIP and reduced glucagon levels. Postprandial insulin levels were unaffected, and vildagliptin treatment was associated with a signifi cant reduction in prandial glucose excursion (incremental area under the curve [AUC] −1.0 mmol/L/h, p Ͻ 0.001), representing a 32% reduction vs placebo. β-cell function, assessed by insulin secretory rate (ISR) relative to glucose measured as ISR AUC 0-2 h /glucose AUC 0-2 h , was signifi cantly increased (+6.4 pmol/min/m 2 /mM, p = 0.002) with vildagliptin. Adverse event profi les were similar for vildagliptin and placebo. No cases of hypoglycemia were reported. Change in body weight was −0.6 kg with vildagliptin and −0.1 kg with placebo.
Mild hyperglycemia
A total of 306 patients with T2DM and mild hyperglycemia (HbA1c 6.2%-7.5%) were randomized to vildagliptin 50 mg qd (n = 156) or placebo (n = 150) for 52 weeks followed by a 4-week washout period (Mari et al 2008; Scherbaum et al 2008a) . At baseline, HbA1c and FPG were 6.7% and 7.1 mmol/L, respectively, in the vildagliptin group and 6.8% and 7.2 mmol/L, respectively, in the placebo group. At 52 weeks, changes in HbA1c were −0.2% with vildagliptin vs +0.1% with placebo (between-group difference p Ͻ 0.001); FPG did not change signifi cantly with vildagliptin (+0.2 mmol/L) and increased with placebo (+0.5 mmol/L, p Ͻ 0.001; between-group difference p = 0.032). Compared with patients on placebo, vildagliptin patients had a signifi cant reduction in 2-hour postprandial glucose (−0.9 mmol/L, p = 0.012) and signifi cantly improved β-cell function assessed as ISR AUC 0-2 h /glucose AUC 0-2 h (+5.0 pmol/min/m 2 /mM, p Ͻ 0.001) (Scherbaum et al 2008a) .
Additional characterization of the effect of vildagliptin on model-assessed β-cell function (Mari 2008) showed that the 0.3% reduction in HbA1c and signifi cantly reduced glucose AUC 0-2 h (−1.7 mM/h, p = 0.002) were accompanied by significantly increased fasting insulin secretory tone (+34.1 pmol/ min/m 2 , p Ͻ 0.001), glucose sensitivity (+20.7 pmol/min/m 2 / mM, p Ͻ 0.001), and rate sensitivity (163.6 pmol/m 2 /mM, p = 0.015), with total insulin secretion (ISR AUC 0-2 h ) and a potentiation factor (expressing relative potentiation of insulin secretory response to glucose) during meals remaining unchanged. Body weight decreased by 0.5 kg with vildagliptin and by 0.2 kg with placebo. Adverse events were similar in the two groups; hypoglycemia occurred in none of the vildagliptin patients and in one placebo patient.
After this study of 52 weeks, a washout period of 4 weeks was built in, followed by continuation of therapy in a subgroup of patients (n = 131). None of the effects of vildagliptin treatment at 52 weeks were present after the 4-week washout period, suggesting absence of a potential disease-modifying effect over 1 year of treatment. The potential for such an effect is suggested by preclinical studies showing that GLP-1, incretin mimetics, and DPP-4 inhibitors inhibit apoptosis, augment β-cell function, and increase β-cell mass in rodent models with a high rate of β-cell turnover (Baggio and Drucker 2006) . However, results of the 52-week extension after the 4-week washout following the core 52-week study (total 104 treatment weeks and 4 weeks washout period) suggest that vildagliptin treatment may attenuate deterioration of β-cell function over 2 years of treatment in mild hyperglycemia (Scherbaum et al 2008b) . Among the 131 patients in the extension study (vildagliptin, n = 68; placebo, n = 63), vildagliptin patients had a signifi cant reduction vs placebo in HbA1c after the second 52-week treatment period (−0.5%, p = 0.008). Placebo-adjusted changes from core study baseline values in FPG, glucose AUC 0-2 h , and ISR AUC 0-2 h / glucose AUC 0-2 h tended to be greater after 2 years than after 1 year of vildagliptin treatment. After the second washout period (week 112), the placebo-adjusted change from week 0 to week 112 in ISR AUC 0-2 h /glucose AUC 0-2 h was 3.2 pmol/ min/m 2 /mM (p = 0.058) and the placebo-adjusted change in HbA1c was −0.3% (p = 0.051), indicating an attenuated rate of loss of glycemic control in the absence of active treatment. Adverse events were similar in the two groups; two placebo patients and no vildagliptin patients had hypoglycemia. Body weight did not change signifi cantly in placebo patients (-0.3 kg) and decreased signifi cantly in vildagliptin patients (−1.1 kg, p = 0.026) compared with core study baseline.
Summary of pooled monotherapy results
Pooled 24-week data from monotherapy arms (data on fi le, Novartis) show that vildagliptin is effective across the range of levels of hyperglycemia and baseline BMI values and in older and younger patients. For all patients receiving 50 mg bid (n = 1569), change in HbA1c from baseline was −1.0%, including changes of −0.6% in those with baseline HbA1c Յ 8.0% (n = 543), −0.9% for baseline HbA1c Ͼ 8.0-9.0% (n = 490), −1.6% for baseline HbA1c Ͼ 9.0%-10.0% (n = 362), and −1.9% for baseline HbA1c Ͼ 10.0% (n = 174) (p Ͻ 0.001 for all compared with baseline). Reductions from baseline HbA1c (8.6%-8.7%) according to BMI with vildagliptin 50 mg bid were 1.1% and 0.9% for Ͻ30 kg/m 2 (n = 819) and Ͼ30 kg/m 2 (n = 748), respectively, and 1.1% and 1.0% for Ͻ35 kg/m 2 (n = 1202) and Ͼ35 kg/m 2 (n = 365), respectively (p Ͻ 0.001 for all vs baseline). Reductions with 50 mg bid were 1.1% in both patients aged Ͻ65 years (n = 1326, baseline 8.7%) and those aged Ͼ65 years (n = 243, baseline 8.4%).
Changes in fasting lipids with vildagliptin treatment were minor, consisting of reductions of 0.6%, 2.7%, and 2.0% in triglycerides, total cholesterol, and LDL cholesterol, respectively, and an increase of 3.9% in HDL cholesterol at the 50 mg bid dose. Rates of peripheral edema were similar to that seen with placebo, consisting of 0.9% with vildagliptin 50 mg qd (n = 655), 1.3% with vildagliptin 50 mg bid (n = 2251), 2.0% with metformin up to 2000 mg/d (n = 252), 4.1% with rosiglitazone 8 mg/d (n = 267), 7.9% with pioglitazone 30 mg/d (n = 216, in a monotherapy arm in a combination study discussed below), and 1.2% with placebo (n = 586). There was a low risk of hypoglycemia, and rates of other clinical adverse events were comparable to those seen with placebo (Table 1) .
Combination therapy
Vildagliptin has been assessed in randomized, double-blind trials as add-on therapy to metformin, SU, thiazolidinedione, and insulin treatment and in initial combination with pioglitazone.
Vildagliptin as add-on to metformin
Add-on to metformin vs placebo A total of 544 patients with inadequate glycemic control (HbA1c 7.5%-11.0%; mean 8.3%-8.4%) on a metformin regimen of Ն1500 mg/d were randomized to vildagliptin 50 mg qd (n = 177) or 50 mg bid (n = 185) or placebo (n = 182) while continuing on metformin for 24 weeks; metformin in all patients was titrated up to Ն2000 mg/d by study baseline, and the mean study dose was 2100 mg/d (Bosi et al 2007a) . HbA1c was reduced by a mean of 0.7% with the addition of vildagliptin 50 mg qd and by 1.1% with vildagliptin 50 mg bid compared with metformin/placebo (both p Յ 0.001) (Figure 1 ). FPG (baseline 9.7-10.1 mmol/L) was reduced by 0.8 mmol/L (p = 0.003) and 1.7 mmol/L (p Ͻ 0.001), respectively, with vildagliptin 50 mg qd and bid. In predefi ned analyses, the addition of vildagliptin 50 mg bid produced changes in HbA1c vs metformin/placebo of −1.3% vs −0.2% in patients aged Ն65 years (vildagliptin, n = 20; metformin/placebo, n = 22; baseline ∼8.3%), −0.8% vs +0.2% in those with baseline BMI Ն 30 kg/m 2 (vildagliptin, n = 103; metformin/placebo, n = 86; baseline ∼8.3%), and −1.3% vs 0.0% in those with baseline HbA1c Ͼ9.0% (vildagliptin, n = 29; metformin/placebo, n = 29) (data on fi le, Novartis). The HbA1c target of Ͻ7.0% was reached in 54% of vildagliptin 50 mg bid patients, 50% of vildagliptin 50 mg qd patients, and 14% of metformin/placebo patients starting treatment with HbA1c Ն8.0% and in 31%, 22%, and 13%, respectively, of those starting at HbA1c Ͼ 8.0%-8.5% (Bosi et al 2007a) . Improved β-cell function with the addition of vildagliptin was shown by signifi cant increases in adjusted mean ISR AUC 0-2 h /glucose AUC 0-2 h with vildagliptin qd (n = 53; +6.9 pmol/min/m 2 /mM) and bid (n = 57; +7.3 pmol/min/m 2 /mM) vs metformin/placebo (n = 54; +1.6 pmol/min/m 2 /mM; p Յ 0.001 for both comparisons); adjusted mean changes in 2-hour postprandial glucose were −1.9, -2.3, and -0.1 mmol/L, respectively (p Յ 0.001 for both vs metformin/placebo) (Bosi et al 2007a) (data on fi le, Novartis).
There were no signifi cant changes in body weight from baseline (mean 93-95 kg) with vildagliptin qd (−0.4 kg) or bid (+0.2 kg) and a signifi cant decrease with metformin/ placebo (-1.0 kg, p Ͻ 0.001) (Bosi et al 2007) . Among patients with baseline DPB Ն 90 mmHg and SBP Ն 140 mmHg (vildagliptin 50 mg bid, n = 57; metformin/placebo, n = 59), reductions in DBP were −4.0 mmHg with vildagliptin 50 mg bid (p Ͻ 0.05) and −0.9 mmHg with metformin/placebo (p = NS) and reductions in SBP were −9.8 (p Ͻ 0.05) and −6.3 (p Ͻ 0.05), respectively. Vildagliptin had a neutral effect on fasting lipids; changes for vildagliptin qd, vildagliptin bid, and metformin/placebo were, respectively, +1.0% (p = 0.014 vs metformin/placebo), +4.8%, and +18.4% for triglycerides; −1.6%, −1.8%, and +1.7% for total cholesterol; +0.4%, +1.8%, and +0.7% for LDL cholesterol; and −0.6%, +0.2%, and +2.0% for HDL cholesterol. Adverse events occurred with similar frequency in all treatment groups (63.3%-65.0%), with GI adverse events occurring in 9.6% of patients (p = 0.022 vs metformin/placebo) on vildagliptin qd, 14.8% of those on vildagliptin bid, and 18.2% of those on metformin/placebo. Mild hypoglycemia occurred in one patient in each group (0.6% with vildagliptin qd, 0.5% with vildagliptin bid, and 0.6% with metformin/placebo).
Add-on to metformin vs pioglitazone add-on
In a noninferiority trial, 576 patients with inadequate glycemic control (HbA1c 7.5%-11.0%; mean ∼8.4%) on stable metformin Ն1500 mg/d were randomized to vildagliptin 50 mg bid (n = 295) or pioglitazone 30 mg qd (n = 281) plus continued metformin for 24 weeks; the metformin dose was titrated up to Ն2000 mg/d by study baseline, and the average study dose was approximately 2000 mg/d (Bolli et al 2008) . Adjusted mean changes in HBA1c were −0.9% with vildagliptin vs −1.0% with pioglitazone, with vildagliptin meeting the noninferiority criterion (Figure 2 ). Among patients with baseline HbA1c Ͼ9.0% (vildagliptin, n = 63; pioglitazone, n = 58; baseline ∼9.7%), HbA1c was reduced by 1.5% in both groups. FPG (baseline mean ∼11.0 mmol/L) was reduced by adjusted means of Vildagliptin oral treatment for T2DM
1.4 mmol/L with vildagliptin and 2.1 mmol/L with pioglitazone, with vildagliptin not meeting the noninferiority criterion. The latter fi nding refl ects differences in mechanism of action of the two agents: insulin-sensitizing thiazolidinediones have more of an effect during fasting, whereas vildagliptin exerts its glucose-dependent effect in the postprandial period. Change in body weight among all patients (baseline ∼91 kg) was +0.3 kg with vildagliptin vs +1.9 kg with pioglitazone (p Ͻ 0.001); the change among patients with baseline BMI Ն 35 kg/m 2 (vildagliptin, n = 73; pioglitazone, n = 70, baseline ∼110 kg) was +0.1 kg with vildagliptin vs +2.6 kg with pioglitazone (p Ͻ 0.001). Adverse events occurred with similar frequency in the vildagliptin and pioglitazone groups (56.4% and 60.0%, respectively). Surprisingly, an unusually high frequency of peripheral edema was reported in vildagliptin patients (8.8%, vs 6.1% with pioglitazone); this fi nding may refl ect the specifi c criteria used for identifying edema in the study and/or the much greater frequency of edema in vildagliptin patients receiving calcium channel blocker therapy vs no edema in pioglitazone patients receiving such concomitant treatment. In another study of initial combination therapy with pioglitazone and vildagliptin, which contained monotherapy arms, peripheral edema was reported in 9.3% of the pioglitazone monotherapy group, 5.2% of the vildagliptin monotherapy group, and 6.1% of the combination therapy group (Bolli et al 2007) . Mild hypoglycemia occurred in one vildagliptin patient and in none of the pioglitazone patients.
Combination with other antidiabetic drugs
Add-on to SU vs placebo A total of 515 patients with inadequate glycemic control on SU monotherapy (HbA1c 7.5%-11.0%; mean 8.5%-8.6%) were randomized to vildagliptin 50 mg qd (n = 170) or 50 mg bid (n = 169) or placebo (n = 176) plus glimepiride 4 mg qd for 24 weeks (Garber 2008) . Placebo-subtracted reductions in HbA1c were 0.6% with vildagliptin qd and 0.7% with vildagliptin bid (both p Ͻ 0.001). Although both reductions were signifi cant, there was no dose response observed with the higher vildagliptin dose; vildagliptin is approved for use in combination with an SU at 50 mg qd. Changes in patients with baseline HbA1c Ͼ 9.0% (vildagliptin qd, n = 32; glimepiride/placebo, n = 4; baseline 9.8%) were −1.0% with vildagliptin 50 mg qd and 0.0% with glimepiride/placebo; changes in patients aged Ն65 years (vildagliptin qd, n = 41; glimepiride/placebo, n = 38; baseline 8.5%) were −0.7% and +0.1%, respectively. Adverse events were similar in frequency with vildagliptin 50 mg qd and with glimepiride/ placebo (67.1% and 64.2%, respectively). Hypoglycemia occurred in two patients (1.2%) receiving vildagliptin 50 mg qd and one patient (0.6%) receiving glimepiride/placebo. Body weight decreased slightly with both treatments (−0.1 kg and −0.4 kg).
Add-on to pioglitazone vs placebo
A total of 463 patients with inadequate glycemic control on thiazolidinedione treatment (HbA1c 7.5%-11.0%, mean 8.6%-8.7%) were randomized to vildagliptin 50 mg qd (n = 147) or 50 mg bid (n = 158) or to placebo (n = 158) plus maximum-dose pioglitazone at 45 mg qd for 24 weeks (Garber et al 2007) . Changes in HbA1c were −0.8% with vildagliptin qd and −1.0% with vildagliptin bid, vs −0.3% with pioglitazone/placebo (p Յ 0.001 for both comparisons). Adverse events were similar in frequency in all groups (48.7%-55.5%). Mild hypoglycemia occurred in none of the patients with vildagliptin qd, in one patient (0.6%) with vildagliptin bid, and in 3 patients (1.9%) with pioglitazone/ placebo. Body weight increased by 1.4 kg with placebo/ pioglitazone and by an additional 0.1 kg with vildagliptin qd and an additional 1.3 kg with vildagliptin bid (p = 0.003 vs placebo/pioglitazone). No consistent or dose-related changes in lipids were observed with the addition of vildagliptin to pioglitazone.
Add-on to insulin vs placebo
A total of 296 patients with inadequate glycemic control on insulin (HbA1c 7.5%-11.0%, baseline ∼8.4%, mean duration of insulin use ∼6 years) received vildagliptin 50 mg bid (n = 144) or placebo (n = 152) plus ongoing insulin for 24 weeks; the mean daily insulin dose at baseline was 81.2-81.9 U, and dose adjustments were permitted during the study (Fonseca 2007) . The change in insulin dose was +1.2 U in the vildagliptin group and +4.1 U in the insulin/placebo group. Changes in HbA1c were −0.5% with vildagliptin and −0.2% with insulin/placebo (p = 0.01); among patients aged Ն65 years (vildagliptin, n = 42; insulin/placebo, n = 41; baseline 8.4%), changes were −0.7% with vildagliptin add-on and −0.1% with insulin/placebo. Vildagliptin was associated with signifi cant reductions in number of hypoglycemic episodes (113 vs 185, p Ͻ 0.001) and number of severe events (0 vs 6, p Ͻ 0.05). The change in body weight was +1.3 kg in vildagliptin/insulin patients and +0.6 kg in insulin/placebo patients.
In an extension of this trial, 96 patients on vildagliptin 50 mg bid continued on treatment and 104 in the insulin/placebo group switched to vildagliptin 50 mg qd plus ongoing insulin for an additional 28 weeks (total 52 weeks) (Fonseca et al 2008) . During the extension phase, the average insulin dose increased by approximately 2 U. At 52 weeks, the effi cacy of vildagliptin 50 mg bid in reducing HbA1c was maintained (−0.5%); in patients receiving vildagliptin 50 mg qd, the change between week 24 and week 52 was −0.4%. In patients aged Ն65 years receiving 50 mg bid, the change in HbA1c at 52 weeks was −0.9%, compared with −0.24% in younger patients, indicating that overall effi cacy primarily refl ected the effect in older patients. There was no signifi cant change in body weight with continued 50 mg bid treatment (+0.3 kg during the extension; +1.8 kg over 52 weeks) or during the extension in patients switched to 50 mg qd (+0.5 kg). The rate of hypoglycemic events per patient-year was 1.80 in the 50 mg bid group and 1.78 in the 50 mg qd group, compared with 2.66 in the insulin/placebo group during the core study; in the elderly patients, event rates were 2.1 and 2.3 in the vildagliptin groups, compared with 3.3 in insulin/placebo patients during the core study.
Initial combination with pioglitazone
A total of 607 treatment-naïve patients (HbA1c 7.5%−11.0%, mean ∼8.7%) were randomized to vildagliptin 100 mg qd (n = 154), pioglitazone 30 mg qd (n = 161), vildagliptin 50 mg qd plus pioglitazone 15 mg qd, or vildagliptin 100 mg qd plus pioglitazone 30 mg qd for 24 weeks (Rosenstock et al 2007b) . Changes in HbA1c were −1.1% with vildagliptin alone, −1.4% with pioglitazone alone, −1.7% with the 50 mg/15 mg combination (p Ͻ 0.05 vs pioglitazone alone), and −1.9% with the 100 mg/30 mg combination (p Ͻ 0.001 vs pioglitazone alone). The target HbA1c level of Ͻ7.0% was achieved in 43%, 43%, 54%, and 65% of patients, respectively (p Ͻ 0.001for the 100 mg/30 mg combination vs both monotherapy groups). Among patients with baseline HbA1c Ͼ 9.0% (average ∼10.0%), reductions were 1.5% with vildagliptin alone (n = 46), 1.8% with pioglitazone alone (n = 54), 2.3% with the 50 mg/15 mg combination (n = 49), and 2.8% with the 100 mg/30 mg combination (n = 54) (p Ͻ 0.001 for the higher-dose combination vs pioglitazone alone). Among patients aged Ն65 years, reductions were 1.3% with vildagliptin alone (n = 17), 1.2% with pioglitazone alone (n = 19), 1.7% with the 50 mg/15 mg combination (n = 15), and 2.3% with the 100 mg/30 mg combination (n = 21) (p Ͻ 0.001 for the higher-dose combination vs pioglitazone alone). Changes in body weight (mean 80-82 kg) were +0.2 kg with vildagliptin monotherapy, +1.5 kg with pioglitazone monotherapy, +1.4 kg with the 50 mg/15 mg combination, and +2.1 kg with the 100 mg/30 mg combination. Adverse event rates were comparable in all groups (45.8%-51.6%). Rates of edema were 5.2% with vildagliptin alone, 9.3% with pioglitazone alone, 3.5% with the 50 mg/15 mg combination, and 6.1% with the 100 mg/30 mg combination. Hypoglycemia occurred in one patient (0.7%) receiving vildagliptin monotherapy and in one (0.7%) receiving the 100 mg/30 mg combination.
Summary of pooled combination study adverse events
Pooled adverse event data from vildagliptin combination studies, shown in Table 2 , indicate good tolerability with vildagliptin in combination with other antidiabetic agents.
Discussion and conclusion
The availability of a new class of agents in our therapeutic toolkit for the treatment of hyperglycemia in T2DM is of great importance to reduce the burden of diabetes. In the new group of inhibitors of DPP-4, vildagliptin proves to be a very effi cacious drug for improving glycemic control in a wide range of T2DM patients, ranging from the IGT population to patients with advanced disease on insulin. Its potential for lowering HbA1c is in the range of that of thiazolidinediones and acarbose in monotherapy, and sustained effi cacy for up to 2 years has been demonstrated. The effect of improving postprandial glycemia provides a good alternative for the up till now limited therapeutic options of affecting postprandial glycemia excursion. In addition, also fasting glycemia is clearly affected by vildagliptin.
Compared to the other gliptins, vildagliptin distinguishes itself by behaving like a surrogate substrate, being altered itself by the enzyme DPP-4 (Ahrén and Foley 2008) . No head-to-head comparison clinical trials between the different gliptins are available at present, so that only indirect comparisons can be made. HbA1c lowering effects seem to be comparable over the spectrum of gliptins, whereas some studies indicate a greater reduction of fasting glycemia for sitagliptin (Amori et al 2007) .
The most interesting combination in which to use vildagliptin is with metformin, for two different reasons. First, from a pathogenic perspective, combining an agent primarily targeting insulin resistance, like metformin, with an agent primarily targeting the β-cell, like vildagliptin, is a logical approach. In addition, the choice of vildagliptin gives the added value of also targeting the α-cell dysfunction that is clearly present in T2DM patients, with insuffi cient suppression of glucagon secretion leading to postprandial hyperglycemia. Second, more than additive effects have been observed with this combination. Indeed, metformin has been found to increase GLP-1 levels, presumably through increasing GLP-1 synthesis rather than DPP-4 inhibition (Hinke et al 2002; Yasuda et al 2002; Migoya et al 2007) . One study found that vildagliptin administration in treatment-naïve patients (n = 5) resulted in a prandial active GLP-1 level of approximately 10 pmol/L and that the addition of vildagliptin in metformintreated patients (n = 12) resulted in a level more than twice as high (p Ͻ 0.05) (Dunning et al 2006) . Based on these reasons, the combination of vildagliptin with metformin will be a (Melikian et al 2002; Blonde et al 2003) and improved glycemic control (Blonde et al 2003) with a fi xed-dose combination of metformin/glyburide than with a free-drug component combination of the two. Investigation of a fi xed-dose combination of vildagliptin 50 mg and metformin 1000 mg showed equivalent plasma concentrations of both vildagliptin and metformin with the fi xed-dose combination compared with the free component combination (He et al 2008c) . The fi xeddose vildagliptin/metformin combination in formulations of vildagliptin 50 mg/metformin 850 mg and vildagliptin 50 mg/metformin 1000 mg was recently approved in the European Union and may thus be a treatment of choice, even early on in the therapy of T2DM patients.
In our efforts to control glucose levels in T2DM patients, effi cacy of the treatment in terms of glucose-lowering potential is, however, only one aspect of therapy. Side effects, such as hypoglycemia and weight gain, or simply overall tolerance of the treatment will determine usability. Vildagliptin presents a very desirable profi le here, with monotherapy studies showing low risk for hypoglycemia, no weight gain, and an incidence of edema, gastrointestinal symptoms, and other adverse events similar to that seen with placebo.
When combining the data on effi cacy and on safety, it is clear that most T2DM patients with suffi cient beta-cell reserve will benefi t from therapy with vildagliptin. Especially patients where hypoglycemia needs to be avoided at all cost, like elderly patients or patients with active professional lives, or where weight gain is a major concern, will benefi t from this treatment (Mathieu and Bollaerts 2007) . The drug profi le makes it a fi rst line choice when thinking of a tool to increase beta-cell insulin secretion.
Vildagliptin is currently approved in the European Union (26 September 2007, European Medicines Agency [EMEA]) for use in combination with metformin and thiazolidinediones at 50 mg bid and with SU at 50 mg qd, with fi xed-dose combinations with metformin (50 mg/850 mg and 50 mg/1000 mg) also available for use (14 November 2007, EMEA) (Galvus EU PI; Eucreas EU PI). Based on observations using higher doses than the ones proposed for clinical use, a caution for liver dysfunction was built in to the label. Vildagliptin should not be used in patients with hepatic impairment. Rare cases of hepatic dysfunction have been reported; therefore, liver function tests should be performed prior to initiation of treatment, at 3-month intervals during the fi rst year, and periodically thereafter.
Whereas vildagliptin may be used throughout the whole spectrum of T2DM patients, an interesting observation was made in patients where vildagliptin was combined with insulin. In these patients, an insulin sparing effect was seen, but more interestingly, less hypoglycemia was observed. No direct explanation is available, but further exploration of this phenomenon is warranted because of great clinical importance.
Finally, there remains the promise of beta-cell protection in the long term. At present, only theoretical considerations and animal data are available, suggesting this will indeed be the case for vildagliptin. In clinical trials, long-term data are scarce, with 2-year data available only recently (Scherbaum et al 2008b) to suggest that in the studied subgroup a change in residual beta-cell function was indeed present in patients treated with vildagliptin for 2 years.
